Agency initiates safety label change and notifies physicians of possible link
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Importantly, the combination of giredestrant and everolimus was well tolerated
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Subscribe To Our Newsletter & Stay Updated